EMvision Medical Devices Ltd. (AU:EMV)
ASX:EMV
Want to see AU:EMV full AI Analyst Report?
EMV Stock Chart & Stats
AU$1.77
-AU$0.06(-3.19%)
At close: 4:00 PM EST
AU$1.77
-AU$0.06(-3.19%)
Day’s Range― - ―
52-Week RangeAU$1.48 - AU$2.43
Previous CloseN/A
Volume36.00K
Average Volume (3M)120.98K
Market Cap
AU$156.63M
Enterprise ValueAU$146.33M
Total Cash (Recent Filing)AU$17.56M
Total Debt (Recent Filing)AU$4.02M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding92,955,560
10 Day Avg. Volume127,185
30 Day Avg. Volume120,982
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)16.01
Price to Sales (P/S)29.42
P/FCF Ratio-18.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.15Price Target Upside77.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.1
Revenue Forecast (FY)AU$5.50M
Bulls Say, Bears Say
Bulls Say
Point-of-care Brain ImagingEMvision’s focus on a portable electromagnetic brain-imaging platform targets a durable, structural need: faster stroke and TBI detection at bedside and in pre-hospital settings. If commercialized, this capability addresses long-term clinical workflow gaps and supports sustained product demand in emergency care.
Moderate LeverageA debt-to-equity of ~0.38 implies conservative financial leverage versus highly indebted peers. This balanced capital structure reduces near-term refinancing pressure and interest burden, preserving financial flexibility to fund continued development or commercialization over the next several months.
Positive FCF-to-income SignalDespite overall negative cash flow, a slightly positive free cash flow-to-net-income ratio signals some operational or capex efficiency and suggests management is extracting relative cash value from reported losses. This efficiency can modestly extend runway and supports incremental progress without immediate large funding rounds.
Bears Say
Steep Revenue DeclineA >30% revenue contraction indicates weakening commercial traction or reduced trial/commercial activity. This undermines scale economics, hampers ability to absorb fixed R&D and G&A costs, and materially raises the risk that further external funding or operational restructuring will be required within a 2-6 month horizon.
Negative Operating Cash FlowPersistently negative operating and free cash flows show the company is burning cash to operate. Continued cash outflows constrain the ability to commercialize, increase dependency on external financing, and elevate dilution and execution risk if revenue inflection is delayed beyond the near term.
Losses And Low ROENegative ROE and sustained operating losses demonstrate the company has not yet translated R&D into profitable operations. Over the medium term this impairs capital attraction, limits reinvestment capacity, and may force strategic shifts or cost cuts that could slow product development and market rollout.
EMvision Medical Devices Ltd. News
EMV FAQ
What was EMvision Medical Devices Ltd.’s price range in the past 12 months?
EMvision Medical Devices Ltd. lowest share price was AU$1.48 and its highest was AU$2.43 in the past 12 months.
What is EMvision Medical Devices Ltd.’s market cap?
EMvision Medical Devices Ltd.’s market cap is AU$156.63M.
When is EMvision Medical Devices Ltd.’s upcoming earnings report date?
EMvision Medical Devices Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 91 days.
How were EMvision Medical Devices Ltd.’s earnings last quarter?
EMvision Medical Devices Ltd. released its earnings results on Feb 22, 2026. The company reported -AU$0.044 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.044.
Is EMvision Medical Devices Ltd. overvalued?
According to Wall Street analysts EMvision Medical Devices Ltd.’s price is currently Undervalued.
Does EMvision Medical Devices Ltd. pay dividends?
EMvision Medical Devices Ltd. does not currently pay dividends.
What is EMvision Medical Devices Ltd.’s EPS estimate?
EMvision Medical Devices Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EMvision Medical Devices Ltd. have?
EMvision Medical Devices Ltd. has 92,955,560 shares outstanding.
What happened to EMvision Medical Devices Ltd.’s price movement after its last earnings report?
EMvision Medical Devices Ltd. reported an EPS of -AU$0.044 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of EMvision Medical Devices Ltd.?
Currently, no hedge funds are holding shares in AU:EMV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EMvision Medical Devices Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$3.15 (77.97% Upside)
AU$3.15 (77.97% Upside)
Blogger Sentiment
Bullish
AU:EMV Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$18.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.44%
12-Months-Change
Fundamentals
Return on Equity
-70.29%
Trailing 12-Months
Asset Growth
25.56%
Trailing 12-Months
Company Description
EMvision Medical Devices Ltd.
EMvision Medical Devices Limited, a medical device company, engages in the research, development, and commercialization of imaging and diagnostic technology products. It develops a portable brain scanner for stroke diagnosis, monitoring, as well as other medical imaging needs. The company was incorporated in 2017 and is based in Macquarie Park, Australia.
EMV Stock 12 Month Forecast
Average Price Target
AU$3.15
▲(77.97% Upside)
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Cyclopharm Limited
―
Aroa Biosurgery Ltd
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---